^(18)F-FLT和^(18)F-FDG早期检测肺癌放疗、化疗疗效的实验研究  

Early detection of tumor response to radiotherapy and chemotherapy in lung carcinoma xenografts by ^(18)F-FLT and ^(18)F-FDG

作　　者：张锦明[1] 朱虹[2] 姚树林[1] 郭喆[1] 柳羲[3] 周乃康[3] 田嘉禾[1] 

机构地区：[1]解放军总医院核医学科,北京100853 [2]南京军区南京总医院核医学科,南京210002 [3]解放军总医院胸外科科,北京100853

出　　处：《功能与分子医学影像学（电子版）》2012年第1期9-13,共5页Functional and Molecular Medical Imaging(Electronic Edition)

基　　金：吴阶平医学基金资助项目(320.6750.08054);核能开发科研技术资助项目(科工二司2009-1228);南京军区医药卫生科研基金(06MA120)

摘　　要：目的与肿瘤显像剂18F-FDG对比,研究18F-FLT早期检测肿瘤经放疗、化疗后的反应。方法荷LA-795肺癌细胞的小鼠,分别接受放疗和化疗。放疗单次剂量为20Gy,分对照组(A组)、放疗后1d组(B组)、放疗后2d组(C组);化疗剂量为腹腔注射0.1mg/ml顺铂/每鼠,分为对照组(D组)、化疗后1d组(E组)、化疗后2d组(F组)。以上各组再分为2亚组,分别注射18F-FDG和18F-FLT,注射后60min处死,测ID﹪/g和增殖细胞抗原(PCNA)值。结果 LA-795肺癌对18F-FLT摄取ID﹪/g低于18F-FDG。18F-FLT检测结果表明,LA-795肺癌无论经放疗还是顺铂化疗,1～2d后肿瘤摄取18F-FLT的ID﹪/g均明显低于对照组(P<0.01)。放疗1、2d,肿瘤摄取18F-FLT分别下降到对照组的53.8﹪和30.5﹪;顺铂化疗1、2d,肿瘤摄取18F-FLT分别下降到对照组的65.6﹪和29.6﹪。放化疗后肿瘤摄取18F-FLT的下降与肿瘤PCNA值下降呈正相关;放疗组的r=0.880(P<0.001),顺铂化疗组的r=0.930(P<0.001)。放疗、顺铂化疗1～2d后LA-795肺癌摄取18F-FDG的ID﹪/g与对照组无明显区别,且ID﹪/g与肿瘤的PCNA相关性不大;放疗组的r=0.359(P=0.085),顺铂化疗组的r=-0.136,P=0.538。结论 18F-FLT是一种与肿瘤增殖相关的显像剂,在早期评价肿瘤放疗或化疗疗效方面比18F-FDG更有价值。Objective 18F-FLT has been suggested as a new PET tracer for tumor proliferation. The uptake of 18F-FLT after 1 and 2 days of radiotherapy or chemotherapy was compared with 18F-FDG to evaluate its potential as an indicator of tumor response in PET imaging. Methods Mice bearing LA-795 lung adeno- carcinoma were irradiated with 20 Gy or treated with single dose of cisplatin （0. lmg）. Mice receiving radiation was randomized to three groups, i.e., control group, Day 1 group, which was evaluated one day after radiation and Day 2 day, which was evaluated two days after radiation. Micw receiving chemotherapy were similarly allocated to three groups. All groups were injected with 18F-FLT and 18F-FDG respectively. The ID %/g and proliferating cell nuclear antigen （PCNA） were detected after injection of radiotracer. Results The ID %/g of LA-795 lung carcinoma in ~SF-FLT was lower than 18F-FDG.The ID %/g of radiotherapy or chemotherapy groups after both one and two days were lower than control groups with tracer of 18F-FLT （P 〈 0.01）. The ID %/g of ISF-FLT in radiotherapy groups decreased to 53.8 % and 30.5 % after one day and two days, respectively. The ID%/g of 18F-FLT in chemotherapy groups decreased to 65.6 % and 29.6 % after one day and two days, respectively. For JSF-FLT, statistical significant correlations were found in both chemotherapy groups and radiotherapy groups between decrease of ID %/g and PCNA （radiotherapy groups and chemotherapy groups： r = 0.880, P 〈 0.001 and r = 0.930, P 〈 0.001, respectively）. In mice injected with 18F-FDG, there were no significant difference in ID %/g among the three groups treated with either irradiation or chemotherapy. No correlation was found between ID %/g and PCNA. Conclusions 18F-FLT, but not 18F-FDG, is suitable for monitoring of early response of tumor proliferation after radiotherapy or chemotherapy.

关 键 词：18F—FDG 18F-FLT 放射性治疗 化疗 疗效 

分 类 号：R734.2[医药卫生—肿瘤] R817.4[医药卫生—临床医学]